The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 The following status statement was

The following article by Laura Spinney appears in BioMednews Reports (6- 25-99,#57) Glycogen storage disease type II causes enlargement of

Orphan Drug Designation A drug becomes an “orphan” when it receives orphan designation from the Office of Orphan Products Development,

Following is background information and a Q & A released by the Pharming/Genzyme LLC on important issues concerning clinical trials

Leiden, the Netherlands/Cambridge, Mass., October 14, 1998—Pharming Group N.V. (Easdaq: PHAR), the Netherlands biopharmaceutical company, and the American biotechnology company